(Reuters) -Inovio Pharmaceuticals Inc said on Tuesday the U.S. Food and Drug Administration (FDA) had lifted a partial clinical hold on late-stage trial of its COVID-19 vaccine within the country.
Inovio said it now has the authorization to proceed with the trial after 14 months, sending its shares up 4.6% before the bell.
The FDA last year in September put the final-stage trial on hold as it sought more information from the company, including details on a delivery device used to inject genetic material into cells.
Following the decision, the U.S. government pulled funding for the late-stage study for Inovio’s vaccine as other COVID-19 vaccines were already available in the country.
Inovio then started late-stage trials outside the United States in partnership with China’s Advaccine Biopharmaceuticals.
The company is currently conducting the Phase 3 portion of its mid-to-late-stage trial in several regions including Latin America, Asia Pacific and Africa.
(Reporting by Manas Mishra and Dania Nadeem in Bengaluru; Editing by Aditya Soni and Shinjini Ganguli)
